Real-World study reveals how breast cancer drugs are actually used down under
NCT ID NCT06624020
First seen Jun 06, 2026 · Last updated Jun 23, 2026 · Updated 3 times
Summary
This completed study looked at medical records of 1128 Australian patients with advanced or metastatic breast cancer to see how doctors prescribe a class of medicines called CDK4/6 inhibitors, including palbociclib. Researchers examined patient characteristics, dosing patterns, and how long people stayed on treatment. No new treatments were given; instead, the study analyzed existing data to describe real-world use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer Australia
Sydney, New South Wales, 2000, Australia
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
palbociclib and other CDK4/6 inhibitors
What this could lead to
If successful, this study could help doctors better understand how these medicines are used in everyday practice, potentially improving treatment guidelines for advanced breast cancer.
What could go wrong
This is a retrospective analysis of existing data, not a controlled trial. It cannot prove cause and effect, and results may not apply to other countries or populations.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.